Home › Compare › SMCBF vs ABBV
SMCBF yields 2046.77% · ABBV yields 3.06%● Live data
📍 SMCBF pulled ahead of the other in Year 1
Combined, SMCBF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SMCBF + ABBV for your $10,000?
The Siam Commercial Bank Public Company Limited provides various financial products and services. The company offers various personal banking products and services, including savings, current, fixed deposit, and long term deposit accounts; payroll solutions; home, car, and personal loans; accident, savings, health expense, and other insurance services; debit, credit, prepaid, and gift cards; mutual funds, bonds, debentures, and other investment products; and payment, digital banking, and other services. It also provides corporate banking products and services comprising credit facilities; financial advisory and merger acquisition services; fixed income instrument and underwriting, structured finance, and project finance services; foreign exchange rate risk management, interest rate risk management, and investment solutions; cash management services; custodian, mutual fund supervisory, registrar, escrow and security agency, debenture's holder representative, and custodian net services; and international trade remittance and digital banking services. In addition, the company engages in the office spaces leasing, hire-purchase, vehicle lending and leasing, and research and development businesses. Further, it provides debt collection services; and food ordering platform and other technological solutions. The company provides its products and services through its head office and branch network in Thailand; and through its branches in Singapore, Hong Kong, Laos, Vietnam, China, and the Cayman Islands. The company is headquartered in Bangkok, Thailand.
Full SMCBF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.